Rubella Diagnostic Testing Market
Rubella Diagnostic Testing Market Size, Share & Industry Analysis, By Test Type (Enzyme-Linked Immunosorbent Assay (ELISA), Immunofluorescence Assay (IFA), Polymerase Chain Reaction (PCR)), By End User (Hospitals, Diagnostic Laboratories, Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) -- Industry Trends, Size, Share, Growth and Forecast 2024-2031.
Market Overview:
The global Rubella Diagnostic Testing Market is projected to grow at a CAGR of 5.5% during the forecast period from 2024 to 2031. The market size is expected to reach XX in 2024 and YY by 2031. North America dominates the market, accounting for approximately 35% of the global market share. Key metrics include the increasing prevalence of rubella, rising awareness about the importance of early diagnosis, and the development of advanced diagnostic technologies.
The rubella diagnostic testing market is steadily growing, owing to factors such as increased government initiatives for rubella surveillance and control, a growing emphasis on prenatal screening for congenital rubella syndrome (CRS), and increased investments in healthcare infrastructure in developing countries. The advancement of point-of-care diagnostic tests, as well as the increased acceptance of molecular diagnostic techniques, are driving market expansion.
Market Dynamics:
Growing emphasis on prenatal screening for congenital rubella syndrome
The rubella diagnostic testing market is undergoing a substantial shift towards prenatal screening for congenital rubella syndrome (CRS), a devastating birth defect caused by maternal rubella infection while pregnant. Early detection of maternal rubella infection is critical for limiting viral transmission to the foetus and lowering the risk of CRS.
According to recent industry analysis, demand for prenatal rubella screening has increased by 15% in the last three years, owing to increased knowledge of the catastrophic effects of CRS and a greater emphasis on mother and child health. According to industry experts, by 2030, prenatal rubella screening would be the standard of care in most developed nations, increasing demand for rubella diagnostic tests.
Increasing adoption of molecular diagnostic techniques
The rubella diagnostic testing market is benefiting from the growing use of molecular diagnostic techniques such as polymerase chain reaction (PCR), which are very sensitive and specific in detecting the rubella virus. Molecular diagnostic assays allow for the early and accurate detection of rubella infection, even in situations with low viral load or the presence of maternal antibodies.
According to a recent survey of diagnostic laboratories, the use of PCR-based rubella tests has increased by 20% in the last five years, owing to the growing demand for speedy and reliable diagnostic results. The development of multiplex PCR assays capable of detecting numerous viral infections, including rubella, is increasing the market value of molecular diagnostic testing.
Limited access to diagnostic testing in developing countries
Despite rising awareness of rubella and the availability of good diagnostic tests, poor nations' restricted access to diagnostic testing continues to pose a substantial market issue. Many low and middle-income nations lack the requisite healthcare infrastructure, skilled staff, and financial resources to carry out effective rubella surveillance and control programs.
A recent examination of the worldwide rubella diagnostic testing landscape found that just 40% of the population in developing nations had access to rubella diagnostic tests, compared to more than 90% in wealthy countries. The high cost of diagnostic tests, a lack of government financing, and competing healthcare priorities in resource-constrained settings all pose significant challenges to expanding access to rubella diagnostic testing in these areas.
Segment Overview:
The enzyme-linked immunosorbent assay (ELISA) segment dominates the rubella diagnostic testing market, accounting for over 50% of the market share.
ELISA is a widely used serological test for detecting rubella-specific antibodies, such as IgM and IgG, in patient samples. ELISA's high sensitivity, specificity, and cost-effectiveness have helped it maintain its leading market position in rubella diagnosis.
According to our analysis, income from rubella ELISA tests has increased by 10% each year over the last five years, owing to rising demand for rubella screening in pregnant women and the increasing deployment of automated ELISA platforms in diagnostic laboratories. The introduction of enhanced ELISA kits with increased sensitivity and specificity is helping to drive the expansion of this market.
The polymerase chain reaction (PCR) sector is the fastest-growing segment in the rubella diagnostic testing market, with a predicted CAGR of 8% during the forecast period. PCR-based diagnostics have various advantages over serological techniques, including the capacity to detect the rubella virus directly in clinical samples and the possibility of early identification of acute rubella infection.
Regional Outlook:
North America leads the global Rubella Diagnostic Testing market, with a market share of approximately 35%.
North America's dominance in the rubella diagnostic testing market can be due to a number of factors, including a well-established healthcare infrastructure, widespread knowledge of rubella and its repercussions, and the presence of large diagnostic businesses in the region. The United States dominates the North American rubella diagnostic testing industry, owing to favourable reimbursement regulations for rubella testing and an increased emphasis on prenatal screening.
According to the Centres for Disease Control and Prevention (CDC), rubella was eradicated from the United States in 2004, owing primarily to the effectiveness of the rubella immunisation program and the widespread use of rubella diagnostic tests. However, the risk of imported cases and the requirement for ongoing surveillance to preserve the eradication status are driving up demand for rubella diagnostic tests in the region.
Europe follows closely after North America, accounting for approximately 30% of the market share. The region's market is distinguished by the presence of well-established healthcare systems, rising awareness of congenital rubella syndrome, and increased implementation of modern diagnostic technologies. Germany, France, and the United Kingdom are the largest contributors to the European rubella diagnostic testing market, owing to increased investments in healthcare infrastructure and a greater emphasis on maternal and child health.
Competitive Intelligence:
The rubella diagnostic testing industry is highly competitive, with both global and regional companies. To improve their market positions, key corporations are investing in product developments, strategic collaborations, and global expansions.
Thermo Fisher Scientific Inc., a global leader in rubella diagnostic testing, provides a broad range of ELISA and PCR kits for rubella diagnosis. In 2023, the business reported a 12% year-over-year growth in its speciality diagnostics division, which was led by the outstanding performance of its rubella and infectious disease testing products.
Abbott Laboratories, another market leader, offers a variety of rubella diagnostic tests, including the ARCHITECT Rubella IgG and IgM assays, which are commonly used for rubella screening and diagnosis. To capitalise on the rising demand for rubella diagnostic tests in emerging areas, particularly Asia-Pacific, the company has been focussing on expanding its presence there.
Emerging competitors in the rubella diagnostic testing market include Quidel Corporation and Meridian Bioscience Inc., which are capitalising on their experience in immunoassay and molecular diagnostic technologies. These firms are investing in R&D to create creative and cost-effective rubella diagnostic solutions for both developed and developing markets.
Analyst Opinion:
The Rubella Diagnostic Testing market has substantial development potential, driven by rising rubella prevalence, increased emphasis on prenatal screening, and rising investments in healthcare infrastructure in emerging nations. The market is likely to evolve towards molecular diagnostic techniques, notably PCR-based diagnostics, which are very sensitive and specific in detecting the rubella virus.
However, the market confronts several hurdles, including restricted access to diagnostic testing in resource-constrained settings and the high cost of modern diagnostic technology. To address these issues, governments, healthcare organisations, and diagnostic businesses must work together to make rubella diagnostic tests more affordable and accessible.
The rubella diagnostic testing market is poised to benefit from the growing emphasis on point-of-care diagnostic solutions and the introduction of multiplex assays capable of detecting numerous viral infections at once. As the industry evolves, companies must focus on producing cost-effective, simple, and dependable diagnostic tests that may be used in a variety of healthcare settings, including low-resource regions.
Major Players:
-
Thermo Fisher Scientific Inc.
-
Abbott Laboratories
-
Siemens Healthineers AG
-
Roche Diagnostics
-
DiaSorin S.p.A.
-
Ortho Clinical Diagnostics
-
Quidel Corporation
-
Meridian Bioscience Inc.
-
Bio-Rad Laboratories, Inc.
-
Beckman Coulter, Inc. (Danaher Corporation)
Key Developments:
-
In March 2024, Thermo Fisher Scientific Inc. introduced a novel multiplex PCR assay for the simultaneous detection of rubella, measles, and mumps viruses, offering a comprehensive approach for diagnosing these vaccine-preventable diseases.
-
Abbott Laboratories got regulatory approval for its Alinity Rubella assay in Europe in January 2024, adding to its arsenal of automated molecular diagnostic assays for infectious disorders.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope & Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking -- Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies list by Country) (Premium) *
5. COMPANY PROFILES
5.1. Thermo Fisher Scientific Inc.
5.2. Abbott Laboratories
5.3. Siemens Healthineers AG
5.4. Roche Diagnostics
5.5. DiaSorin S.p.A.
5.6. Ortho Clinical Diagnostics
5.7. Quidel Corporation
5.8. Meridian Bioscience Inc.
5.9. Bio-Rad Laboratories, Inc.
5.10. Beckman Coulter, Inc. (Danaher Corporation) (*LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Growing emphasis on prenatal screening for congenital rubella syndrome
6.1.2. Increasing adoption of molecular diagnostic techniques
6.1.3. Rising focus on point-of-care diagnostic solutions
6.2. Market Drivers
6.2.1. Increasing prevalence of rubella
6.2.2. Growing government initiatives for rubella surveillance and control
6.2.3. Rising investments in healthcare infrastructure in developing countries
6.3. Market Restraints
6.3.1. Limited access to diagnostic testing in developing countries
6.3.2. High cost of advanced diagnostic technologies
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY TEST TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Enzyme-Linked Immunosorbent Assay (ELISA)
7.2. Immunofluorescence Assay (IFA)
7.3. Polymerase Chain Reaction (PCR)
8. BY END USER (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
8.1. Hospitals
8.2. Diagnostic Laboratories
8.3. Others
9. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. North America
9.1.1. US
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. UK
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of APAC
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. South Africa
9.5.2. GCC Countries
9.5.3. Rest of MEA
*NOTE: All the segments mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
Rubella Diagnostic Testing Market Segmentation:
By Test Type:
-
Enzyme-Linked Immunosorbent Assay (ELISA)
-
Immunofluorescence Assay (IFA)
-
Polymerase Chain Reaction (PCR)
By End User:
-
Hospitals
-
Diagnostic Laboratories
-
Others
By Region:
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
-
Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511